From The Motley Fool · Lee Samaha · · 40s
Viking Therapeutics Raises $575M for Obesity Stock
Viking Therapeutics secured $575 million to fund obesity drug trials and pipeline development.
In brief
Viking Therapeutics secured $575 million to fund obesity drug trials and pipeline development. Viking Therapeutics raised $575 million to support obesity drug trials and pipeline development. Originally reported by The Motley Fool.
Viking Raises $575M
Viking Therapeutics raised $575 million through a stock offering and convertible senior notes.
Why Cash Is Needed
Viking needs cash to fund large phase 3 trials for its obesity drug VK2735 and pipeline development.
Trials in Progress
Viking is running 78-week phase 3 trials for VK2735 in obesity and type 2 diabetes with obesity.
Future Trials Timeline
VK2735 oral trials are expected to conclude in 2028, with results hitting in 2027.
In short
Viking Therapeutics raised $575 million to support obesity drug trials and pipeline development.
